Gamida Cell Ltd

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Gamida Cell (the “Company”), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new executive leadership following a successful restructuring transaction ("Transaction”) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) on May 24, 2024. As part of the Transaction, Highbridge invested $30 million of new capital into Gamida Cell, and is expected to provide substantial additional capital to s.

Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management

Gamida Cell (NASDAQ: GMDA ) stock is falling hard on Wednesday after the clinical-stage biopharmaceutical company announced major changes to its business in its Q4 earnings report. This big news here is the company entering into a Restructuring Support Agreement (RSA) with funds managed by Highbridge Capital Management.

Why Is Gamida Cell (GMDA) Stock Down 82% Today?

Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript

Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge ® (omidubicel-onlv)

Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management

Company announces commencement of restructuring process  supported by Highbridge Capital Management Continued progress of launch of Omisirge ® (omidubicel-onlv), with the delivery of six units in 2023, as well as significant transplant center onboarding Company to host conference call today at 8:30 a.m. ET BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd.

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024.

Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubicel-onlv)

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction. However, there can be no assurance that the company's strategic alternatives process will result in any such transaction.

Gamida Cell Actively Pursuing Strategic Alternatives

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it will present new data on its FDA approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings will take place virtually and in person at the Henry B. González Convention Center in San Antonio, Texas, February 21-24.

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought leader Gary Schiller, MD, FACP, Professor of Medicine and Director of the Hematological Malignancy & Stem Cell Transplant Program at the David Geffen School of Medicine at University of California – Los Angeles.

Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.

Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

Gamida Cell Ltd. (NASDAQ:GMDA ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President & Chief Executive Officer Michele Korfin - Chief Operating Officer & Chief Commercial Officer Ronit Simantov - Chief Medical Officer & Chief Scientific Officer Terry Coelho - Chief Financial Officer Conference Call Participants Gil Blum - Needham & Co. Operator Ladies and gentlemen, thank you for standing by.

Gamida Cell Ltd. (GMDA) Q3 2023 Earnings Call Transcript

Company continues to advance launch, reports initial revenue from Omisirge ® (omidubicel-onlv)

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

Data further characterize the mechanism for Gamida Cell's proprietary nicotinamide (NAM) technology's expansion and enhancement of cells Data further characterize the mechanism for Gamida Cell's proprietary nicotinamide (NAM) technology's expansion and enhancement of cells

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the third quarter ended September 30, 2023 and provide an update on the company on Tuesday, November 14, 2023.

Gamida Cell to Report Third Quarter 2023 Financial Results

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new early data in 10 patients with CD20 positive non-Hodgkin lymphoma enrolled in the first three cohorts in an ongoing multicenter Phase 1 study of natural killer (NK) cell therapy candidate GDA-201. The study is designed to evaluate safety and determine the maximum tolerated dose. Enrolled patients were heavily pretreated with a median of six prior.

Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today issued an update on its operations in Israel. “We remain profoundly saddened by the attacks in Israel this weekend and express our deepest condolences to the people of Israel as they mourn the loss of loved ones and defend themselves,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. “We have been in touch with our employees in Israel.

Gamida Cell Issues Update on Israel Operations

Compugen

Kamada

Protalix Biotherapeutics

Taro Pharmaceutical Industries

Teva Pharmaceutical

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California, and livestreamed globally. Ms. Jenkins will also participate in a panel titled “A record setting year for cell and gene therapies – how do we keep the mome.

Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that it will be presenting at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023) taking place in San Diego, CA and virtually November 1-5, 2023. Details about the poster presentations are as follows: Title: GDA-201, nicotinamide (NAM) expanded NK cells derived from peripheral apheresis, show unique culture kinetics and increase.

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the first patient has received a stem cell transplant with Omisirge (omidubicel-onlv). “This is a significant milestone for Gamida Cell, advancing our mission of delivering potentially curative therapies to patients with cancer,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. “This patient will be the first of many who.

First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming H.C. Wainwright 25th Annual Global Investment Conference in New York, NY. Presentation Details Format: Fireside chat Date and time: Available on-demand Monday, September 11, 2023, at 7 a.m. ET for conference registrants The Gamida Cell management team will be available for one.

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference

Gamida Cell's approved therapy, Omisirge, shows faster neutrophil recovery and reduced infections in blood cancer patients compared to standard care. The long-term study of Omisirge includes a diverse patient population, improving its marketability. Cash headwinds continue to be a challenge, and their latest financial filings do not ease this uncertainty.

Gamida Cell: The Treacherous Path To Profitability

Gamida Cell Ltd. (NASDAQ:GMDA ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President and CEO Michele Korfin - COO and Chief Commercial Officer Ronit Simantov - Chief Medical Officer and Scientific Officer Terry Coelho - CFO Conference Call Participants Jason Butler - JMP Securities Operator Ladies and gentlemen, thank you for standing by.

Gamida Cell Ltd. (GMDA) Q2 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the quarter ended June 30, 2023. “Since the approval of Omisirge in April, Gamida Cell has made excellent progress on the launch,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. “We have rapidly confirmed significant payer coverage and are seeing high interest from transpl.

News for Gamida Cell Ltd Stock (GMDA)